Cargando…
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance
Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association be...
Autores principales: | Ho, Matthew, Zanwar, Saurabh, Buadi, Francis K., Ailawadhi, Sikander, Larsen, Jeremy, Bergsagel, Leif, Binder, Moritz, Chanan-Khan, Asher, Dingli, David, Dispenzieri, Angela, Fonseca, Rafael, Gertz, Morie A., Gonsalves, Wilson, Go, Ronald S., Hayman, Suzanne, Kapoor, Prashant, Kourelis, Taxiarchis, Lacy, Martha Q., Leung, Nelson, Lin, Yi, Muchtar, Eli, Roy, Vivek, Sher, Taimur, Warsame, Rahma, Fonder, Amie, Hobbs, Miriam, Hwa, Yi L., Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474409/ https://www.ncbi.nlm.nih.gov/pubmed/36096078 http://dx.doi.org/10.1182/blood.2022017616 |
Ejemplares similares
-
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
por: Zanwar, Saurabh, et al.
Publicado: (2022) -
Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
por: Zanwar, Saurabh, et al.
Publicado: (2022) -
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
por: Pang, Li, et al.
Publicado: (2021) -
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021) -
P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)